SCHEMBL31409460

SCHEMBL31409460

COc1cc2c(cc1OC)C(C(=O)O)C2

nearest known ligand 0.49

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.44
TRPV1 Q8NER1 1/20 0.43
CYP3A4 P08684 1/20 0.42
MAPT P10636 1/20 0.42
ALDH1A1 P00352 1/20 0.41
ACHE P22303 1/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
CA12 O43570 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL547260 1.00 SMN1; SMN2 (0.44) SMN1; SMN2TRPV1CYP3A4MAPTALDH1A1
SCHEMBL547259 1.00 SMN1; SMN2 (0.44) SMN1; SMN2TRPV1CYP3A4MAPTALDH1A1
SCHEMBL547261 1.00 SMN1; SMN2 (0.44) SMN1; SMN2TRPV1CYP3A4MAPTALDH1A1
SCHEMBL15188762 0.86 SMN1; SMN2 (0.48) SMN1; SMN2CYP3A4MAPTACHE
SCHEMBL15188760 0.86 SMN1; SMN2 (0.48) SMN1; SMN2CYP3A4MAPTACHE
SCHEMBL15188761 0.86 SMN1; SMN2 (0.48) SMN1; SMN2CYP3A4MAPTACHE
SCHEMBL3130145 0.84 SMN1; SMN2 (0.43) SMN1; SMN2TRPV1CA1CA2
SCHEMBL12182386 0.84 SMN1; SMN2 (0.43) SMN1; SMN2CYP3A4MAPT
SCHEMBL548190 0.84 SMN1; SMN2 (0.43) SMN1; SMN2TRPV1CA1CA2
SCHEMBL9722208 0.83 NQO2 (0.51) SMN1; SMN2TRPV1ALDH1A1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4734977-A2 NOVEL TRPV1 AGONISTS AND USES THEREOF Neucures, Inc. (US) 2026-05-06 EP disclosed
WO-2025006675-A9 NOVEL TRPV1 AGONISTS AND USES THEREOF NEUCURES, INC. (US) 2025-03-13 WO disclosed
WO-2025006675-A2 NOVEL TRPV1 AGONISTS AND USES THEREOF NEUCURES, INC. (US) 2025-01-02 WO disclosed